Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

CGRP (Calcitonin Gene-Related Peptide) peptide icon, one bubble per amino acidCGRP (Calcitonin Gene-Related Peptide)37 residuesACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

CGRP (Calcitonin Gene-Related Peptide)

6.9 min half-life·Injection·1w on / 4w off

Also known as: alpha-CGRP, CGRP-alpha, CGRP-I

Between 10 and 1,000 times more potent than acetylcholine at relaxing small blood vessels, depending on the review. CGRP (Calcitonin Gene-Related Peptide) is a 37-amino-acid neuropeptide that became the molecular foundation for the most successful migraine drug class developed in the past two decades. Four monoclonal antibodies and three small-molecule gepants now target this single peptide pathway. The peptide itself, however, remains a research-only compound. A plasma half-life of 6.9 minutes and potent hypotensive effects have kept exogenous CGRP confined to controlled IV infusion studies. Researchers use it to probe trigeminal neurovascular physiology, cardiovascular regulation, and wound healing biology.

What Is CGRP (Calcitonin Gene-Related Peptide)?

Calcitonin Gene-Related Peptide, or CGRP (alpha isoform, encoded by the CALCA gene; CAS 83652-28-2), is a 37-amino-acid neuropeptide and one of the most potent microvascular vasodilators identified to date (PMID 23162536 (opens in a new tab)). Reviews put it 10 to 1,000 times more potent than acetylcholine at widening small blood vessels (PMID 25287861 (opens in a new tab), PMID 23162536 (opens in a new tab)). Four FDA-approved monoclonal antibodies and three gepant receptor blockers exist because of this single molecule.

The path from peptide to drug target started with two findings. Goadsby and colleagues [1] measured raised CGRP in jugular venous blood during spontaneous migraine attacks. Then Lassen's group [2] showed in 2002 that a 20-minute IV CGRP infusion gave all nine analyzed migraine patients a headache. Three had migraine-like attacks. That provocation model became the foundation for developing erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), eptinezumab (Vyepti), ubrogepant (Ubrelvy), rimegepant (Nurtec), and atogepant (Qulipta), all approved between 2018 and 2022.

Beyond migraine, CGRP shows cardioprotective properties in ischemia-reperfusion models and accelerates wound closure in diabetic mouse models (Lu YZ et al., Nature 2024)[3]. But the peptide itself has no approved therapeutic indication. That 6.9-minute plasma half-life requires continuous IV infusion, and the potent systemic vasodilation makes outpatient use impractical. CGRP remains a research tool, not a therapeutic product.

How CGRP (Calcitonin Gene-Related Peptide) Works

CGRP binds a heterodimeric receptor built from calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). A third protein, receptor component protein (RCP), locks in the G protein coupling.

Once CGRP docks onto CLR/RAMP1, the primary cascade runs through Gs signaling. Adenylyl cyclase fires up, intracellular cyclic AMP (cAMP) rises, and protein kinase A (PKA) gets to work. In vascular smooth muscle, PKA phosphorylates KATP channels and myosin light chain phosphatase. Both actions relax the muscle wall and dilate the vessel. Some vascular beds add an endothelium-dependent layer; CGRP activates endothelial nitric oxide synthase (eNOS), releasing nitric oxide for additional vasodilation.

The receptor also signals through beta-arrestin pathways after internalization into endosomes. Sustained cAMP production continues inside the cell even after plasma CGRP is gone. That endosomal signaling likely explains why vasodilatory effects persist 20 to 40 minutes beyond the peptide's 6.9-minute clearance.

In trigeminal sensory neurons, CGRP released from peripheral terminals in the dura triggers a cascade: dural vasodilation, mast cell degranulation, plasma protein extravasation, and sensitization of second-order trigeminocervical neurons. This is the core pathophysiology of migraine. CGRP also sensitizes its own release from neighboring neurons, creating a positive feedback loop that sustains and amplifies the attack.

CGRP (Calcitonin Gene-Related Peptide) Benefits

  • CGRP benefits center on vasodilation, cardioprotection, and neurovascular biology.
  • Between 10 and 1,000 times more potent than acetylcholine at widening small blood vessels, depending on the review (Russell 2014, PMID 25287861 (opens in a new tab); Kokkoris 2012, PMID 23162536 (opens in a new tab)). Both rank it among the most potent vasodilators known.
  • Reduces infarct size in ischemia-reperfusion injury models through PKC-epsilon and KATP channel-dependent ischemic preconditioning pathways.
  • An engineered eCGRP construct accelerated wound closure roughly 2.5x in diabetic mouse models (Lu YZ et al., Nature 2024)[3], driven by keratinocyte proliferation and microvascular perfusion.
  • Gastroprotective: maintains mucosal blood flow and suppresses gastric acid secretion in the GI tract.
  • Anti-hypertensive properties confirmed in preclinical models of both pulmonary and systemic hypertension.
  • Neuroprotective effects shown in stroke and traumatic brain injury animal models, with reduced infarct volume and improved functional recovery scores.

CGRP (Calcitonin Gene-Related Peptide): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 13 key studies·Research only

CGRP is one of the most potent microvascular vasodilators identified (PMID 23162536 (opens in a new tab)) and the central molecular target in migraine pathophysiology.

Dosing studied: IV infusion for 20 minutes. The migraine provocation standard is 1.5 mcg/min, 30 mcg total (PMID 37815254); Lassen 2002 used 2 mcg/min (PMID 11993614). Kraenzlin 1985 gave synthetic rat CGRP at about 0.09 to 0.7 mcg/min for a 70 kg adult (PMID 3922013). The 3 mcg/min (60 mcg) top of the tier range is unsourced. SC route: no established dose (unsourced).
Read the evidence (key study, limitations)

Exogenous CGRP infusion is validated as the gold-standard migraine provocation model. Cardioprotective and wound-healing effects are documented in preclinical models; no approved human therapeutic indication exists for the peptide itself.

Key Study

Lassen LH et al. (Cephalalgia 2002, PMID 11993614): a 20-minute IV CGRP infusion caused headache in all 9 analyzed migraineurs and migraine-like attacks in 3. Goadsby PJ et al. (1990, PMID 2454066): serum CGRP elevated in jugular blood during spontaneous migraine attacks. Lu YZ et al. (Nature 2024, PMID 38538784): engineered eCGRP construct accelerated wound closure ~2.5x in diabetic mouse models.

Limitations

6.9-minute half-life requires continuous IV infusion; no human therapeutic trials for cardioprotection or wound healing have completed Phase II. 2024 wound healing data (PMID 38538784) used an ECM-anchored eCGRP construct, not native peptide. No full-length agonist CGRP with extended half-life has reached clinical trials as of October 2026 (ClinicalTrials.gov).

Community Experience
Weak
3.5/5
Based on 0 self-administration reports across r/Peptides, r/PeptidesForRecovery, or biohacking forums as of April 2026

No self-administration community exists for exogenous CGRP peptide.

Community dosing: N/A: no self-administration protocols exist
Read the reports (common issues 5)

Discussion on r/migraine (~200K members) focuses exclusively on FDA-approved anti-CGRP monoclonal antibodies. Zero documented cases of consumer peptide self-injection confirmed across all major peptide communities as of April 2026.

What users report (0)
    Common issues (5)
    • IV-only route is an insurmountable barrier to self-administration
    • 6.9-minute half-life makes subcutaneous use impractical for sustained effects
    • 99% flushing rate at research infusion doses
    • Reliable migraine provocation in susceptible individuals (60–75%)
    • Potent hypotension requiring continuous hemodynamic monitoring and vasopressor standby
    Science-Only Evidence

    No community self-administration exists. All protocols and evidence derive exclusively from controlled clinical research settings with IV infusion and hemodynamic monitoring. Community discussion of the CGRP pathway concerns FDA-approved anti-CGRP antibody drugs, not the peptide itself.

    CGRP (Calcitonin Gene-Related Peptide) Dosage Guide

    SpeculativeVery limited human dosing data: extrapolated from migraine provocation studies, which infused 1.5 to 2 mcg/min for 20 minutes (PMID 37815254, 11993614), so the 60 mcg tier (3 mcg/min) is unsourced; therapeutic antibodies differ in dose
    LevelDose / InjectionFrequency
    Beginner10 mcgSingle dose
    Moderate30 mcgSingle dose
    Aggressive60 mcgUnsourced: no cited study infused 3 mcg/min. Cited infusions ran 1.5 to 2 mcg/min for 20 minutes, 30 to 40 mcg in total (PMID 37815254, 11993614).Single dose
    Note:

    CGRP is not a self-administration peptide. This needs to be stated plainly because the peptide shows up in search results alongside injectable peptides that people do use at home. The 6.9-minute half-life means subcutaneous injection produces a brief, unpredictable hemodynamic event with no sustained benefit. Every published human study used IV infusion with continuous blood pressure monitoring.

    Infusion prep is a job for the research pharmacy, not a home step. The migraine provocation standard is 1.5 mcg/min for 20 minutes, 30 mcg in total. That dose is diluted into normal saline and run through an infusion pump, so there is no syringe draw to work out.

    The detail most people miss: CGRP adsorbs to glass and plastic surfaces at low concentrations. Below 10 mcg/mL, add 0.1% BSA (bovine serum albumin) as a carrier protein and use siliconized or protein low-bind containers. Skip this step and your actual delivered dose could be noticeably lower than intended.

    Cycling Protocol

    On Period
    1 weeks
    Off Period
    4 weeks

    No established human cycling protocol exists for exogenous CGRP administration. The extremely short half-life (~6.9 minutes) necessitates continuous IV infusion for sustained effects, which is impractical outside controlled research settings. Human infusion studies have typically used single-dose protocols (1.5 to 2 mcg/min for 20 minutes). Repeated dosing may lead to tachyphylaxis of vasodilatory responses. Cycling parameters shown are theoretical placeholders. Any investigational use requires continuous hemodynamic monitoring.

    Calculate your CGRP (Calcitonin Gene-Related Peptide) dose
    Dosing tiers, timing, and cycle length

    Or use the universal Peptide Calculator for any peptide.

    CGRP (Calcitonin Gene-Related Peptide) Protocols by Goal

    advancedClinical TrialSingle 20-minute infusion session
    IV Infusion: Migraine Provocation
    Wk Single session
    1.5 mcg/min × 20 min (30 mcg total) · Single infusion · Intravenous infusion

    Expected: Immediate vasodilation, flushing (~99%), BP reduction 10–30 mmHg systolic, reflex tachycardia. Delayed migraine-like headache in 60–75% of migraine-susceptible subjects within 1–5 hours post-infusion.

    Monitor: Continuous BP, HR, and SpO2 during infusion. Record headache onset/severity hourly for 12 hours. IV vasopressor (phenylephrine 50–100 mcg or norepinephrine) on standby.

    How to Use CGRP (Calcitonin Gene-Related Peptide)

    1. 1
      Step 1

      Confirm setting: continuous blood pressure monitoring (intra-arterial line preferred), ECG telemetry, peripheral IV access, and vasopressor (phenylephrine 50 to 100 mcg IV) on standby. Subject supine.

    2. 2
      Step 2

      Pharmacy prep: the research pharmacy dissolves the lyophilized peptide and dilutes the session dose into normal saline for the infusion pump. Gently swirl until dissolved. Do not vortex. Nothing is drawn into a syringe for injection.

    3. 3
      Step 3

      Set the pump: the standard 1.5 mcg/min rate gives 30 mcg over 20 minutes. Use protein low-bind tubing; add 0.1% BSA to the diluent if the concentration falls below 10 mcg/mL.

    4. 4
      Begin infusion at target rate

      Record baseline blood pressure and heart rate immediately before starting.

    5. 5
      Step 5

      Monitor continuously: BP and HR every 1 to 2 minutes during infusion. Alert thresholds are systolic drop greater than 20 mmHg from baseline, absolute systolic below 90 mmHg, or sustained HR above 130 bpm.

    6. 6
      Step 6

      Stop infusion immediately if: systolic BP drops more than 30 mmHg, HR exceeds 130 sustained, SpO2 falls below 92%, or subject requests discontinuation.

    7. 7
      Step 7

      Post-infusion monitoring: keep subject supine for 60 minutes minimum. Record headache severity (VAS or NRS) at 30 min, 1h, 2h, 4h, and 12h. Do not allow standing until BP returns within 10 mmHg of baseline.

    8. 8
      Step 8

      Storage: reconstituted solution is stable for up to 48 hours at 2 to 8 degrees C. Do not refreeze. Prepare fresh on study day when possible.

    Alternative Routes

    Intravenous infusion (standard research route)

    Cited infusions ran 1.5 to 2 mcg/min for 20 minutes, 30 to 40 mcg total (PMID 37815254, 11993614); the 60 mcg tier (3 mcg/min) is unsourced. Reference route (100% bioavailability).

    Infusion pump required. Peripheral IV line adequate; central line preferred for high-dose protocols. Continuous hemodynamic monitoring mandatory.

    Subcutaneous injection (investigational)

    Unsourced: no SC dose has been established. The 10 to 60 mcg figures are the IV infusion totals, not a tested SC dose. No established SC protocol in modern literature.

    Local erythema and warmth at injection site expected (local vasodilatory effect). Hemodynamic monitoring still required. Not used in contemporary migraine or cardioprotection research protocols.

    CGRP (Calcitonin Gene-Related Peptide) Stacking Protocols

    Works With

    Avoid

    Antihypertensive agents (all classes: ACE inhibitors, ARBs, calcium channel blockers, diuretics)

    Additive hypotension with CGRP-mediated vasodilation. Risk of severe, potentially refractory hemodynamic compromise.

    Do not combine
    Nitrates and PDE5 inhibitors (sildenafil, tadalafil, vardenafil)

    Amplified NO-mediated and cAMP-mediated vasodilation. Severe hypotension risk. Contraindicated combination.

    Do not combine
    Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab)

    Direct pharmacological antagonism: mAbs block the CLR/RAMP1 receptor or CGRP ligand, negating exogenous CGRP effects and creating unpredictable pharmacology.

    Do not combine
    Gepants (ubrogepant/Ubrelvy, rimegepant/Nurtec, atogepant/Qulipta)

    Small-molecule CGRP receptor antagonists. Block CLR/RAMP1 activation by exogenous CGRP. Active elimination half-lives of 5–11h may persist at time of any CGRP infusion.

    Do not combine

    Estimated Cost

    Generic / Research
    Research-grade alpha-CGRP: ~$200–$450 per 1 mg lyophilized vial (lab-reagent pricing). Custom bulk synthesis: ~$80–$180/mg at scale. No gray-market consumer supply identified.

    Pricing updated 2026-04-09

    CGRP (Calcitonin Gene-Related Peptide) Side Effects

    Profound, dose-dependent hypotension is the most serious risk with exogenous CGRP. IV infusion studies report systolic blood pressure drops of 10 to 30 mmHg. At high doses, blood pressure can fall far enough to require IV fluid bolus or vasopressor intervention with phenylephrine (50 to 100 mcg IV). This is not a mild inconvenience; it's a medical event that demands continuous hemodynamic monitoring and vasopressor standby before any infusion begins.

    Facial flushing occurs in virtually all subjects at pharmacological doses. Published figures put it at approximately 99%. The flushing reflects CGRP's vasodilatory mechanism acting on cutaneous vasculature. Warmth, cutaneous erythema, and a sensation of heat throughout the body accompany the flushing.

    Reflex tachycardia follows the blood pressure drop. Heart rate increases as the cardiovascular system compensates for reduced vascular resistance. A 2026 FAERS analysis [5] flagged palpitation signals across the entire CGRP pathway drug class, raising the monitoring bar even further.

    The migraine provocation effect is perhaps the most distinctive side effect of any peptide. In migraine-susceptible individuals, CGRP infusion triggers delayed migraine-like attacks. In the 2023 REFORM study, 110 of 139 people with migraine (79%) had one within 12 hours of a 20-minute infusion [6]. This reflects sustained trigeminal sensitization rather than ongoing peripheral CGRP activity, since the peptide clears in under 7 minutes.

    Nausea, dizziness, and lightheadedness related to blood pressure reduction are common during and immediately after infusion.

    Long-term effects of exogenous CGRP are unknown. All published human data comes from single infusions or very short courses. Theoretical concerns include exacerbation of inflammatory conditions (CGRP drives neurogenic inflammation) and interference with bone metabolism.

    Contraindications are strict. Hypotension or hemodynamic instability, active migraine, severe cardiovascular disease, concurrent potent antihypertensives, pregnancy, and breastfeeding all disqualify a subject. Administration outside a setting with continuous hemodynamic monitoring, IV access, and vasopressor availability is not appropriate for any reason.

    Common Issues & Solutions

    Hypotension (>20 mmHg systolic drop): Have IV fluid bolus (250–500 mL saline) and vasopressor (phenylephrine 50–100 mcg IV) ready before infusion starts. Keep subject supine during infusion and 30–60 min after. Do not allow standing until BP returns to within 10 mmHg of baseline.

    Surface adsorption at low concentrations: CGRP adsorbs strongly to glass and polypropylene at concentrations below ~10 mcg/mL. Add 0.1% BSA as carrier protein to diluent and use siliconized or protein low-bind containers for accurate dosing at research concentrations.

    Delayed migraine headache (1–5h post-infusion): Pre-screen subjects for migraine history if provocation is not the study endpoint. If headache develops, sumatriptan 50–100 mg oral or 6 mg SC is effective and validates the CGRP mechanism of the headache.

    Solution instability: Reconstituted CGRP is highly labile. Use within 48 hours at 2–8°C. Do not freeze reconstituted solution; multiple freeze-thaw cycles abolish activity. Prepare fresh on the study day when possible.

    Tachyphylaxis on repeat infusion: Vasodilatory response can diminish with repeated CGRP infusions in the same session (CLR/RAMP1 internalization). Allow ≥30 min between infusions and confirm baseline hemodynamic recovery before re-dosing.

    Ask AI about this page

    Ask AI for a second opinion on CGRP (Calcitonin Gene-Related Peptide) dosing and side effects

    Contraindications

    • Hypotension or hemodynamic instability: CGRP causes potent vasodilation
    • Active migraine or history of frequent migraine attacks: CGRP infusion triggers migraine-like headache
    • Severe cardiovascular disease including decompensated heart failure
    • Concurrent use of potent antihypertensive agents: risk of additive hypotension
    • Pregnancy and breastfeeding: insufficient safety data; potential effects on placental blood flow
    • Known hypersensitivity to CGRP or calcitonin family peptides
    • Severe hepatic impairment affecting peptide clearance
    • Raynaud phenomenon or vasospastic conditions (paradoxical rebound risk)
    • Settings without continuous hemodynamic monitoring and vasopressor access
    • Pediatric populations (no safety data for exogenous administration)

    Drug Interactions

    • Antihypertensive agents (all classes): additive hypotension with CGRP-mediated vasodilation
    • Nitrates and phosphodiesterase-5 inhibitors (sildenafil, tadalafil): amplified vasodilation and severe hypotension risk
    • Triptans (sumatriptan, rizatriptan): functional antagonism; triptans inhibit CGRP release from trigeminal neurons
    • Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab): direct pharmacological antagonism
    • CGRP receptor antagonists (gepants: ubrogepant, rimegepant, atogepant): block CGRP receptor activation
    • Calcium channel blockers: additive vasodilation and hemodynamic effects
    • Beta-blockers: may blunt compensatory tachycardia, worsening hypotensive episodes
    • ACE inhibitors and ARBs: additive blood pressure reduction
    • Capsaicin (high-dose): depletes CGRP from sensory nerve terminals; may reduce endogenous CGRP reserve
    • Botulinum toxin (onabotulinumtoxinA): inhibits CGRP release from trigeminal neurons; used therapeutically in chronic migraine
    • Small-molecule CGRP receptor antagonists. Block CLR/RAMP1 activation by exogenous CGRP. Active elimination half-lives of 5–11h may persist at time of any CGRP infusion.

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Continuous blood pressure (intra-arterial line preferred; cuff minimum)Throughout infusion and for 60 min post-infusionAlert threshold: systolic >20 mmHg drop from baseline or absolute systolic <90 mmHg
    Heart rate / ECG telemetryThroughout infusion and 60 min post-infusionAlert threshold: HR >130 bpm sustained or symptomatic palpitations
    Headache severity (VAS 0–10 or NRS)Baseline, end of infusion, then at 30 min, 1h, 2h, 4h, 12h post-infusionNot listed
    Plasma CGRP concentration (research settings)Pre-infusion, during infusion peak, 7 min, 20 min, and 40 min post-infusionNot listed
    Skin temperature / forearm blood flow (laser Doppler or plethysmography)During infusion in vascular physiology studiesNot listed
    Continuous blood pressure (intra-arterial line preferred; cuff minimum)

    CGRP causes dose-dependent hypotension (10–30 mmHg systolic). Real-time monitoring required for both safety and dose-response characterization.

    Heart rate / ECG telemetry

    Reflex tachycardia is expected; FAERS 2026 (PMID 41706150) documents class-wide palpitation signals across all CGRP pathway drugs. ECG characterizes rhythm and excludes arrhythmia.

    Headache severity (VAS 0–10 or NRS)

    CGRP provokes delayed migraine-like headache in 60–75% of susceptible subjects. Primary efficacy/safety endpoint in migraine research protocols.

    Plasma CGRP concentration (research settings)

    Characterizes PK (t½ ~6.9 min) and confirms dose delivery. Measured by RIA or LC-MS/MS. Required for PK studies; optional for provocation studies.

    Skin temperature / forearm blood flow (laser Doppler or plethysmography)

    Objective measure of peripheral vasodilation response for dose-response characterization.

    CGRP (Calcitonin Gene-Related Peptide) Before and After

    Minutes 0-5

    Rapid onset of vasodilatory effects following IV infusion. Facial flushing and warmth detectable within 1-2 minutes. Measurable reduction in systemic vascular resistance and blood pressure. Heart rate increases reflexively. Peak plasma CGRP concentrations achieved during infusion.

    Minutes 5-20

    Sustained vasodilation during infusion period. Blood pressure nadir typically reached during or shortly after the infusion. Skin temperature elevation in extremities. In migraine-susceptible individuals, premonitory migraine symptoms may begin (photophobia, nausea). cAMP-mediated smooth muscle relaxation at maximal effect.

    Minutes 20-40

    After infusion cessation, plasma CGRP levels decline rapidly (t1/2 ~6.9 minutes). Hemodynamic parameters begin normalizing within 10-15 minutes post-infusion. Flushing resolves. However, endosomal CLR/RAMP1 signaling may sustain intracellular cAMP elevation beyond peptide clearance.

    1-5 hours post-infusion

    Plasma CGRP fully cleared. In migraine-susceptible subjects, delayed migraine-like headache develops in 60-75% of individuals, typically peaking 1-5 hours post-infusion. This delayed headache likely reflects sustained trigeminal sensitization and central processing rather than ongoing peripheral CGRP signaling.

    6-24 hours post-infusion

    Complete resolution of direct hemodynamic effects. Migraine-like headache, if triggered, may persist for hours and responds to standard migraine treatments including triptans. Cardioprotective effects observed in preclinical ischemia models peak during the early reperfusion period following CGRP pre-treatment.

    What to Expect

    Minutes 0 to 5: Vasodilation begins fast. Facial flushing and warmth show up within 1 to 2 minutes of starting the IV infusion. Systemic vascular resistance drops measurably. Heart rate climbs as a reflex response. Plasma CGRP hits peak concentration while the infusion runs.

    Minutes 5 to 20: Blood pressure reaches its lowest point around 10 to 15 minutes into the infusion. Skin temperature rises in the extremities. cAMP-mediated smooth muscle relaxation is at full effect. Migraine-susceptible individuals may start noticing premonitory symptoms like photophobia or nausea during this window.

    Minutes 20 to 40: After the infusion stops, plasma CGRP drops rapidly with a half-life of about 6.9 minutes. Hemodynamic numbers start returning to baseline within 10 to 15 minutes. Flushing fades. But endosomal CLR/RAMP1 signaling can keep intracellular cAMP raised longer than the peptide stays in circulation.

    1 to 5 hours post-infusion: Plasma CGRP is completely cleared by this point. The delayed headache window opens. In 60 to 75% of migraine-susceptible subjects, a migraine-like headache develops and typically peaks during this period. The headache reflects central trigeminal sensitization, not residual peripheral CGRP activity.

    6 to 24 hours post-infusion: All direct hemodynamic effects have resolved. If a migraine-like headache was triggered, it responds to standard migraine treatments including triptans (sumatriptan 50 to 100 mg oral or 6 mg subcutaneous). No documented next-day effects from a single infusion session.

    Detailed Timeline: Science vs Community

    Minutes 0–5
    Science

    Facial flushing and warmth detectable within 1–2 minutes. Measurable reduction in systemic vascular resistance. Reflex tachycardia begins. Peak plasma CGRP concentrations during infusion.

    Community

    N/A: research setting only

    Minutes 5–20
    Science

    Sustained vasodilation. BP nadir typically at 10–15 min into infusion. Skin temperature elevation in extremities. Maximal cAMP-mediated smooth muscle relaxation. Premonitory migraine symptoms may begin in susceptible individuals.

    Community

    N/A

    Minutes 20–40
    Science

    Post-infusion plasma CGRP declines rapidly (t½ ~6.9 min). Hemodynamics begin normalizing within 10–15 min of infusion end. Flushing resolves. Endosomal CLR/RAMP1 signaling may sustain intracellular cAMP elevation beyond peptide clearance.

    Community

    N/A

    1–5 hours post-infusion
    Science

    Plasma CGRP fully cleared. Delayed migraine-like headache develops in 60–75% of migraine-susceptible subjects. Reflects sustained trigeminal sensitization and central processing, not ongoing peripheral CGRP signaling.

    Community

    N/A

    6–24 hours post-infusion
    Science

    Complete resolution of hemodynamic effects. Provoked headache (if present) responds to standard migraine treatment. No known next-day effects from a single infusion.

    Community

    N/A

    Pharmacokinetics

    Half-Life
    7min
    Bioavailability
    IV: 100% (reference route); SC: no human data
    Tmax
    IV: during infusion; SC: no human data
    Data Confidence
    moderate

    Source: Plasma t1/2 of immunoreactive CGRP is approximately 6.9 minutes (the fast phase of a two-phase decay) in humans given synthetic rat CGRP by IV infusion (Kraenzlin et al., 1985, PMID 3922013). No single clearance route is established; mast cell tryptase and matrix metalloproteinase-2 both cleave CGRP (Kokkoris et al., 2012, PMID 23162536)

    Pharmacokinetics: Active Dose Over Time

    t½ = ~6.9 minutes (alpha-CGRP)

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    37
    Structure
    Cyclic
    Sequence
    ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers
    CAS: 83652-28-2 (human alpha-CGRP)PubChem 56841902 (opens in a new tab)

    Who Should Consider CGRP (Calcitonin Gene-Related Peptide)

    • Migraine and headache neuroscience researchers
    • Cardiovascular researchers studying endogenous vasodilatory mechanisms
    • Wound healing and tissue repair investigators
    • Pain neuroscience researchers studying trigeminal neurovascular physiology
    • Pharmacologists studying GPCR signaling through CLR/RAMP complexes
    • Vascular biologists investigating angiogenesis and ischemia-reperfusion injury

    Related Peptides

    What Changed for CGRP (Calcitonin Gene-Related Peptide)

    1. Dosing

      Oct 18, 2026: CGRP's 60 mcg tier now carries its unsourced note; cited infusions ran 1.5 to 2 mcg/min for 20 minutes, per PubMed (PMID 11993614).

      Before: Aggressive 60 mcg single dose with no note After: Aggressive 60 mcg single dose, noted: unsourced; cited infusions ran 1.5 to 2 mcg/min for 20 minutes (30 to 40 mcg)

      What this does not mean: The tiers did not change. The printed chart and the page now show the same note the dosing guide already gave.

      Source: Cephalalgia 2002, CGRP may play a causative role in migraine (Lassen et al.): 2 mcg/min IV for 20 minutes (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

    2. Evidence

      Corrected Oct 12, 2026: CGRP infusion set off migraine-like attacks in 79% of people with migraine (110 of 139), not 60 to 75%, per PubMed (PMID 37815254).

      Before: Delayed migraine-like headache in 60 to 75% of subjects, peaking 1 to 5 hours after infusion (cited to PMID 11952980, an unrelated paper) After: Delayed migraine-like attacks in 110 of 139 people with migraine (79%) within 12 hours of a 20-minute infusion (REFORM, PMID 37815254)

      What this does not mean: Not a new risk: CGRP infusion is the standard way studies provoke migraine. The old line cited a PMID that points to an unrelated paper.

      Source: Cephalalgia 2023, An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study (Al-Khazali et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

    Peptide Schedule Research TeamReviewed Apr 7, 202613 Citations

    References

    1. [1]Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]CGRP may play a causative role in migraine (Lassen et al., Cephalalgia 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
    3. [3]CGRP sensory neurons promote tissue healing via neutrophils and macrophages (Nature 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]Calcitonin gene-related peptide and its role in migraine pathophysiology (Eur J Pharmacol 2004) (opens in a new tab)PubMed (opens in a new tab)Review
    5. [5]Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists from FDA AERS (Xu et al., Naunyn Schmiedebergs Arch Pharmacol 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
    6. [6]An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: a REFORM study (Al-Khazali et al., Cephalalgia 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed

    Related Tools

    Storage & Stability

    Before Reconstitution
    Up to 24 months at -20°C, desiccated, protected from light
    After Reconstitution
    Up to 48 hours at 2-8°C; extremely labile in solution, use promptly after reconstitution
    Temperature
    -20°C lyophilized; 2-8°C (36-46°F) reconstituted

    Frequently Asked Questions

    During a migraine attack, trigeminal sensory neurons release excessive CGRP, causing dural vasodilation and central sensitization. Anti-CGRP antibodies block this excess from acting at its receptor. Exogenous CGRP infusion mimics the excess seen during attacks; it doesn't treat migraine, it provokes it. The drugs target pathologically elevated CGRP, not the peptide's normal physiological role.

    Alpha-CGRP (37 AA, encoded by CALCA via alternative splicing of calcitonin mRNA) predominates in sensory and central nervous system neurons; this is the isoform relevant to migraine and vascular physiology. Beta-CGRP (37 AA, 94% sequence homology, encoded by CALCB) is primarily expressed in enteric neurons.

    Emerging signal. A 2024 Neurology study found a modestly increased composite cardiovascular risk with CGRP inhibitor initiation. CGRP is cardioprotective, so blocking it long-term could theoretically reduce ischemic protection. Short-term clinical trial data (25,000+ patient-years) has not shown MACE increase, but this remains under active surveillance.

    The 6.9-minute half-life requires continuous IV infusion, impractical for chronic use. Potent systemic vasodilation limits dosing and causes hypotension. And the anti-CGRP drug class arrived and captured commercial interest in the pathway before agonist development could compete.

    Active investigation. The cardioprotective application (ischemia-reperfusion injury) may be compatible with a single-dose or brief infusion protocol. Modified CGRP analogs with longer half-lives are in preclinical development but none have reached clinical trials as of 2026.